Fractyl Secures FDA Approval for Weight Maintenance Study After Discontinuation of GLP-1s
April 1, 2024
The FDA’s Investigational Device Exemption (IDE) clears the way for a pivotal study of Fractyl’s Revita system designed to maintain weight loss after patients have stopped taking GLP-1 drugs